Scheitz, J. F.; Gensicke, H.; Zinkstok, S. M.; Curtze, S.; Arnold, Marcel; Hametner, C.; Pezzini, A.; Turc, G.; Zini, A.; Padjen, V.; Wegener, S.; Nordanstig, A.; Kellert, L.; Kagi, G.; Bejot, Y.; Michel, P.; Leys, D.; Nolte, C. H.; Nederkoorn, P. J. and Engelter, S. T. (2018). Cohort profile: Thrombolysis in Ischemic Stroke Patients (TRISP): a multicentre research collaboration. BMJ open, 8(9), e023265. BMJ Publishing Group 10.1136/bmjopen-2018-023265
|
Text
e023265.full.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (242kB) | Preview |
PURPOSE: The ThRombolysis in Ischemic Stroke Patients (TRISP) collaboration aims to address clinically relevant questions about safety and outcomes of intravenous thrombolysis (IVT) and endovascular thrombectomy. The findings can provide observational information on treatment of patients derived from everyday clinical practice. PARTICIPANTS: TRISP is an open, investigator-driven collaborative research initiative of European stroke centres with expertise in treatment with revascularisation therapies and maintenance of hospital-based registries. All participating centres made a commitment to prospectively collect data on consecutive patients with stroke treated with IVT using standardised definitions of variables and outcomes, to assure accuracy and completeness of the data and to adapt their local databases to answer novel research questions. FINDINGS TO DATE: Currently, TRISP comprises 18 centres and registers >10 000 IVT-treated patients. Prior TRISP projects provided evidence on the safety and functional outcome in relevant subgroups of patients who were excluded, under-represented or not specifically addressed in randomised controlled trials (ie, pre-existing disability, cervical artery dissections, stroke mimics, prior statin use), demonstrated deficits in organisation of acute stroke care (ie, IVT during non-working hours, effects of onset-to-door time on onset-to-needle time), evaluated the association between laboratory findings on outcome after IVT and served to develop risk estimation tools for prediction of haemorrhagic complications and functional outcome after IVT. FUTURE PLANS: Further TRISP projects to increase knowledge of the effect and safety of revascularisation therapies in acute stroke are ongoing. TRISP welcomes participation and project proposals of further centres fulfilling the outlined requirements. In the future, TRISP will be extended to include patients undergoing endovascular thrombectomy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Arnold, Marcel |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2044-6055 |
Publisher: |
BMJ Publishing Group |
Language: |
English |
Submitter: |
Panagiota Milona |
Date Deposited: |
04 Feb 2019 16:56 |
Last Modified: |
05 Dec 2022 15:25 |
Publisher DOI: |
10.1136/bmjopen-2018-023265 |
PubMed ID: |
30224398 |
Uncontrolled Keywords: |
functional outcome registry revascularization stroke thrombectomy thrombolysis Associates GmbH and travel support from Bayer and Boehringer-Ingelheim HG has received research support from the Swiss National Science Foundation AZ has received funding for speaker honoraria and consulting fees from Boehringer-Ingelheim and Medtronic-Covidien and consulting fees from Nestec GK received grants from Swiss Parkinson Association, Swiss Heart Association, Swiss National Science Foundation and served on advisory boards for Boehringer-Ingelheim, Bayer, Daiichi Sankyo (Schweiz) AG, Zambon, Nestle, GE Healthcare within the last two years YB received honoraria or consulting fees from AstraZeneca France, Daiichi-Sankyo, BMS-Pfizer, Covidiem, Bayer and MSD France PM received research grants from the Swiss National Science Foundation, the Swiss Heart Foundation speaker fees from Boehringer-Ingelheim, Bayer, Covidien and Stryker honoraria from scientific advisory boards from Boehringer-Ingelheim, Bayer, Pfizer, Amgen consulting fees from Pierre-Fabre and Astra-Zeneca and travel support from Boehringer-Ingelheim and Bayer. All this support is received by the institution (CHUV) and is used for stroke education and research DL participated during the last 5 years to 1 advisory boards, symposia or trials sponsored by Sanofi Aventis, BMS, Astrazeneca, Boeringher-Ingelheim, Servier, Ebewe, CoLucid Pharm, Brainsgate, Photothera, Lundbeck, GSK, Bayer, Pfizer et Allergan (honorarium paid to Adrinord or research account of the hospital) and was an associated editor of the Journal of neurology, neurosurgery and psychiatry 2004-2010 (personal financial compensation) CHN has received funding for travel or speaker honoraria from Bayer, Boehringer-Ingelheim, Takeda, and BMS/Pfizer PJN has received consulting fees from Boehringer-Ingelheim STE has received funding for travel or speaker honoraria from Bayer and Boehringer-Ingelheim, he has served on scientific advisory boards for Bayer, Boehringer-Ingelheim, BMS/Pfizer and Covidien and on the editorial board of Stroke. He has received an educational grant from Pfizer and research support from the Science Funds (Wissenschaftsfonds) of the University Hospital Basel, the University Basel, the Swiss Heart Foundation and the Swiss National Science Foundation. |
BORIS DOI: |
10.7892/boris.124771 |
URI: |
https://boris.unibe.ch/id/eprint/124771 |
Actions (login required)
 |
Edit item |